Target intelligence / Profile preview

MicroRNA-483-3p (miR-483-3p)

Target
miR-483-3p
Molecular classification
MicroRNA, Non-coding RNA
01

Overview

MicroRNA-483-3p (miR-483-3p) is a small non-coding RNA molecule located within the second intron of the insulin-like growth factor 2 (IGF2) gene [1]. It plays a critical role in post-transcriptional gene regulation by binding to the 3' untranslated regions (UTRs) of various target mRNAs, such as PUMA and SMAD4, thereby inhibiting their translation or promoting their degradation [2]. miR-483-3p is frequently dysregulated in several human malignancies, including hepatocellular carcinoma and adrenocortical tumors, where it often acts as an oncomiR by promoting cell survival and proliferation [3]. Beyond oncology, it is implicated in metabolic disorders such as polycystic ovary syndrome (PCOS) and type 2 diabetes, as well as cardiovascular conditions [4]. Therapeutic strategies currently focus on the use of antisense oligonucleotides (antagomirs) to inhibit its activity in overexpressing tissues or miRNA mimics to restore function where it is lost. However, clinical translation is challenged by the need for precise delivery systems and the potential for off-target effects due to the broad regulatory network of the miRNA. Sources: [1] NCBI Gene ID: 406914; [2] Veronese et al. (2010) Cancer Research; [3] Soon et al. (2009) J Clin Endocrinol Metab; [4] Long et al. (2019) J Clin Endocrinol Metab.

Other names
hsa-miR-483-3pMIR483MicroRNA 483
02

Mechanism of action

Binds to the 3' untranslated region (UTR) of target mRNAs to induce translational repression or mRNA degradation [1].

03

Biological functions

Gene expression regulation [1]Cell proliferation [2]Apoptosis [2]Cell cycle regulation [3]Metabolic regulation [4]
04

Disease associations

Cancer [2]Hepatocellular carcinoma [3]Colorectal cancer [3]Adrenocortical carcinoma [3]Polycystic ovary syndrome [4]Cardiovascular disease [1]Type 2 diabetes [4]
05

Safety considerations

Off-target effectsSystemic toxicityDelivery vehicle immunogenicitySaturation of the RNA-induced silencing complex (RISC)
06

Interacting drugs

Antagomir-483-3p (Experimental)

1 more in the full profile.

07

Biomarkers

Circulating miR-483-3p levels [3]Serum miR-483-3p [3]

Beyond the preview

Go deeper on MicroRNA-483-3p (miR-483-3p).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA-483-3p (miR-483-3p).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call